Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antibiotic Firms Push Ahead With cSSSI Trials, Despite Lack Of FDA Guidance

Executive Summary

Antibiotic developers with unpartnered compounds are forging ahead with late-stage trials for complicated skin and skin structure infections, or cSSSI, even though they are still awaiting FDA's formal guidance on drug development in this area

You may also be interested in...



Paratek's Antibiotic Nuzyra Survived 20 Years – Now For The US Launch

Company still mulling pricing for broad-spectrum antibiotic Nuzyra (omadacycline), which is set to launch in the US in the first quarter, following FDA approval Oct. 2.

Emboldened By Strong Data, Optimer Licenses Antibiotic Candidate To Astellas

Just days after the publication of promising data concerning its antibiotic drug candidate fidaxomicin, Optimer Pharmaceuticals Inc. has licensed the compound to Astellas Pharma Europe Ltd. to treat Clostridium difficile infections in Europe and additional territories

Emboldened By Strong Data, Optimer Licenses Antibiotic Candidate To Astellas

Phase III data showing an improved relapse rate relative to the standard of care drove the deal, which could be worth up to $214 million.

Related Content

Topics

UsernamePublicRestriction

Register

PS051681

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel